Clinical Trial AI Patient-Protocol Matching
One-Liner
An AI platform matching patient phenotypes from EHR data against clinical trial protocol eligibility criteria, helping pharma companies and CROs find eligible patients faster to reduce drug development timelines.
AI Thinking Process
AI platform matching patient EHR phenotypes against trial protocol eligibility criteria. Drug development timeline compression from 30-50% creates bottleneck shift from finding drugs to finding patients.
Immediate red flag: TrialMatch (ASCO), Antidote (acquired by TrialSpark), Deep 6 AI (EHR patient identification), Tempus/Flatiron Health (Roche), Unlearn AI. Major players since 2020.
KILLED — occupied market. Multiple well-funded competitors for 5+ years. No structural gap exists in patient matching specifically.
Kill Reason
Saturated market. Multiple well-funded competitors have been building AI patient-trial matching for 5+ years: Deep 6 AI (AI patient identification from EHR data), TrialSpark and Antidote (acquired, AI matching), Tempus and Flatiron Health/Roche (oncology data with trial matching), Unlearn AI (digital twins for trials). The AI clinical trial platformization signal is real but the patient matching component has been competed since 2020.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.